Clinical trials

Bone Mass and Osteoporosis​

A study conducted by Amorphical in this field compared the fractional absorption and bone-building activity of calcium between two groups of postmenopausal women, who were given identical doses of amorphous calcium carbonate (ACC) and crystalline calcium carbonate (CCC). CCC is currently the most common commercially available calcium supplement, and therefore serves as a baseline for comparison with other calcium supplements.

The results of this study show that fractional calcium absorption (FCA) from ACC is on average twice higher compared to CCC. We also found a significant negative correlation between the baseline FCA from CCC and the improved FCA from ACC. In other words, patients with low gastrointestinal absorption of calcium from CCC showed higher than the average improvement in FCA after administration of ACC. These findings support the hypothesis that ACC’s gastrointestinal absorption mechanism is different from what is conventionally known, which consists of the absorption of dissolved calcium ions through the intestine walls. 1

Similarly, in one of Amorphical’s preclinical studies that used ovariectomized rats as a model for prevention and treatment of osteoporosis, the calcium bioavailability was significantly increased in the animals treated with ACC compared to the CCC group.2 An examination of bone density and physical structure (femur and 4th lumbar vertebra) revealed that:

1. Bone mass density (BMD) was higher in the animals treated with ACC compared to CCC and untreated ones;

2. The bones of animals treated with ACC were better structured, and therefore stronger.

The findings of both these studies suggest that ACC’s high bioavailability (because of its different activity and absorption mechanisms) should help increase BMD.

Skip to content